GlassScriptPhysician profile
Michael J Zarilla
NPI 1386865574
$6,386.12
in general payments reported to CMS, 2019-2025
41 companies · $1,624 in 2025
The $1,624 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $770 · 2022: $880 · 2023: $1,631 · 2024: $1,480 · 2025: $1,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,735.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,010.74 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $606.54 | 2021-2025 | |
| Novo Nordisk INC | $569.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $554.15 | 2023-2025 | Korlym |
| Pfizer INC. | $462.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $450.48 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $376.66 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.03 | 2021-2024 | Jardiance, Synjardy |
| Amgen INC. | $290.72 | 2021-2025 | Repatha, Otezla, Tepezza |
| Boston Scientific Corporation | $172.85 | 2023-2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $136.54 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $133.54 | 2021-2025 | Capvaxive |
| Novartis Pharmaceuticals Corporation | $132.99 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $109.52 | 2022-2024 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $104.33 | 2023-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $96.45 | 2022-2025 | Freestyle Libre 2, Aveir, Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $95.12 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Exact Sciences Corporation | $70.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $60.92 | 2023-2025 | Veozah |
| Aimmune Therapeutics, INC. | $59.74 | 2024-2025 | Zenpep |
| Jazz Pharmaceuticals INC. | $47.74 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.55 | 2023 | |
| Tandem Diabetes Care, INC. | $44.61 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $38.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.01 | 2022 | |
| Phathom Pharmaceuticals, INC. | $36.59 | 2024-2025 | Voquezna |
| Almatica Pharma LLC | $35.87 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Recordati_rare_diseases_inc. | $29.80 | 2025 | Isturisa |
| Daiichi Sankyo INC. | $29.25 | 2024 | Injectafer |
| Mylan Specialty L.P. | $27.47 | 2023-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.45 | 2025 | Caplyta |
| Mannkind Corporation | $22.43 | 2025 | |
| Chiesi USA, INC. | $22.42 | 2025 | Mycapssa |
| Kyowa Kirin, INC. | $21.66 | 2023 | Crysvita |
| Idorsia Pharmaceuticals US INC | $18.98 | 2022 | |
| Radius Health, INC. | $17.36 | 2024 | Tymlos |
| Dexcom, INC. | $17.13 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $15.34 | 2023 | Unithroid |
| Sequel Med Tech, LLC | $15.23 | 2025 | Twiist |
| Kowa Pharmaceuticals America, INC. | $12.87 | 2021 | |
| Genentech USA, INC. | $10.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zarilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.